Stocks Health care XGN
NASDAQ · Health careExagen Inc. (XGN)
Exagen Inc. brought in $71.1M of revenue over the twelve months to June 30, 2026, up 20.8% from a year earlier. It posted a net loss of $18.9M. In fiscal 2025 capital spending exceeded operating cash flow by $14.3M. At June 30, 2026 it held $24.6M in cash against $22.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Exagen Inc.
- Net worth
- Exagen Inc. has a market value (market cap) of $172M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $66.6M (+19.7% year on year), with a net loss of $20M. Over the 12 months to June 30, 2026: revenue $71.1M, net loss $18.9M.
- Cash flow
- In fiscal 2025 operations used $13.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Exagen Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Exagen Inc. does
Exagen Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker XGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $66.6M | -$20M | -$0.93 | -$14.3M |
| 2024 | $55.6M | -$15.1M | -$0.83 | -$13.8M |
| 2023 | $52.5M | -$23.7M | -$1.34 | -$15.3M |
| 2022 | $45.6M | -$47.4M | -$2.77 | -$36.5M |
| 2021 | $48.3M | -$26.9M | -$1.68 | -$22.6M |
| 2020 | $42M | -$16.7M | -$1.32 | -$14.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XGN ranks in Health care
Latest SEC filings
What Exagen Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $19.9M versus the same quarter last year; diluted EPS -$0.13 versus -$0.21.
- August 4, 2026
- June 9, 2026
- May 27, 2026Passive stake (5% or more) SCHEDULE 13G
- May 20, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 12% to $17.3M versus the same quarter last year; diluted EPS -$0.17 versus -$0.20.
- May 11, 2026
- April 27, 2026
- April 27, 2026Additional proxy material DEFA14A
Insider trades
What the people running Exagen Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $104.4K and sold $418.6K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 19, 2026 | Chernett Jorey10% owner | Bought | 14,000 | $104.4K |
| October 16, 2026 | Aballi JohnPresident and CEO, Director | Sold | 34,294 | $269.8K |
| September 1, 2026 | Black Jeffrey G.Chief Financial Officer | Sold | 20,614 | $148.8K |
| September 1, 2026 | Black Jeffrey G.Chief Financial Officer | Received as pay | 1,571 | $4.7K |
| March 12, 2026 | Black Jeffrey G.Chief Financial Officer | Received as pay | 75,000 | $237K |
| March 12, 2026 | Aballi JohnPresident and CEO, Director | Received as pay | 150,000 | - |
| March 3, 2026 | Aballi JohnPresident and CEO, Director | Sold | 15,698 | $56.8K |
| March 3, 2026 | Aballi JohnPresident and CEO, Director | Received as pay | 2,535 | $7.8K |
Who owns XGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chernett Jorey13G, passive | 9.9% | May 20, 2026 |
| NMSIC Co-Investment Fund, L.P.13G, passive with 1 related filers | 6.04% | February 11, 2026 |
| Parian Ultreia LP13G, passive | 5.3% | May 27, 2026 |
| Cowen Financial Products LLC13G, passive | 5% | May 12, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 57 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Wexford Capital LP | 792,855 | 0 |
| Nano Cap New Millennium Growth Fund L P | 675,000 | +90,000 |
| First Eagle Investment Management, LLC | 613,930 | +488,688 |
| Vanguard Capital Management LLC | 612,832 | -65,820 |
| FourWorld Capital Management LLC | 596,528 | +156,578 |
| Silvercrest Asset Management Group LLC | 514,761 | -23,109 |
| Kennedy Capital Management LLC | 485,048 | -8,612 |
| Mink Brook Asset Management LLC | 475,944 | +106,917 |
| Jane Street Group, LLC | 322,502 | +85,767 |
| Marshall Wace, Llp | 306,703 | +279,414 |
| Flputnam Investment Management Co | 288,810 | new |
| Rtw Investments, LP | 195,000 | -200,231 |
| Geode Capital Management, LLC | 185,654 | +6,797 |
| Man Group plc | 167,292 | +37,582 |
| BlackRock, Inc. | 142,625 | +16,739 |
| Perceptive Advisors LLC | 114,893 | 0 |
| XTX Topco Ltd | 111,948 | -130,337 |
| Sei Investments Co | 109,005 | -135,235 |
| Squarepoint Ops LLC | 108,993 | -179,832 |
| Vanguard Fiduciary Trust Co | 108,649 | +11,350 |
Insiders
3 insiders reported holding 3,748,990 shares in total, about $19.7M at the last price.
| Holder | Shares |
|---|---|
| Chernett Jorey10% owner | 2,618,540 |
| Aballi JohnPresident and CEO, Director | 805,540 |
| Black Jeffrey G.Chief Financial Officer | 324,910 |
Questions about XGN
What does Exagen Inc. do?
Exagen Inc. is a company in the Health care sector, listed on NASDAQ as XGN. Its shares trade on NASDAQ under the ticker XGN.
What is Exagen Inc.'s net worth?
Exagen Inc. has a market value (market cap) of $172M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Exagen Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.9M on revenue of $71.1M.
How much revenue does Exagen Inc. make?
Over the twelve months to June 30, 2026 Exagen Inc. reported revenue of $71.1M. That is 20.8% more than a year earlier.
When did Exagen Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 2, 2026.
When is Exagen Inc.'s next earnings report?
Exagen Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare XGN with
Follow XGN
Get an email when Exagen Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Exagen Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.